Natalie A Bello1, Brian Claggett1, Akshay S Desai1, John J V McMurray1, Christopher B Granger1, Salim Yusuf1, Karl Swedberg1, Marc A Pfeffer1, Scott D Solomon2. 1. From the Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (N.A.B., B.C., A.S.D., M.A.P., S.D.S.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (J.J.V.M.); Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC (C.B.G.); Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada (S.Y.); and Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden (K.S.). 2. From the Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (N.A.B., B.C., A.S.D., M.A.P., S.D.S.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (J.J.V.M.); Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC (C.B.G.); Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada (S.Y.); and Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden (K.S.). ssolomon@rics.bwh.harvard.edu.
Abstract
BACKGROUND: Hospitalization for acute heart failure (HF) is associated with high rates of subsequent mortality and readmission. We assessed the influence of the time interval between previous HF hospitalization and randomization in the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) trials on clinical outcomes in patients with both reduced and preserved ejection fraction. METHODS AND RESULTS:CHARM enrolled 7599 patients with New York Heart Association class II to IV HF, of whom 5426 had a history of previous HF hospitalization. Cox proportional hazards regression models were used to assess the association between time from previous HF hospitalization and randomization and the primary outcome of cardiovascular death or unplanned admission to hospital for the management of worsening HF during a median of 36.6 months. For patients with HF and reduced or preserved ejection fraction, rates of cardiovascular mortality and HF hospitalization were higher among patients with previous HF hospitalization than those without. The risk for mortality and hospitalization varied inversely with the time interval between hospitalization and randomization. Rates were higher for patients with HF and reduced ejection fraction within each category. Event rates for those with HF with preserved ejection fraction and a HF hospitalization in the 6 months before randomization were comparable with the rate in patients with HF and reduced ejection fraction with no previous HF hospitalization. CONCLUSIONS:Rates of cardiovascular death or HF hospitalization are greatest in those who have been previously hospitalized for HF. Independent of EF, rates of death and readmission decline as time from HF hospitalization to trial enrollment increased. Recent HF hospitalization identifies a high-risk population for future clinical trials in HF and reduced ejection fraction and HF with preserved ejection fraction. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00634400.
RCT Entities:
BACKGROUND: Hospitalization for acute heart failure (HF) is associated with high rates of subsequent mortality and readmission. We assessed the influence of the time interval between previous HF hospitalization and randomization in the Candesartan in Heart failure: Reduction in Mortality and morbidity (CHARM) trials on clinical outcomes in patients with both reduced and preserved ejection fraction. METHODS AND RESULTS: CHARM enrolled 7599 patients with New York Heart Association class II to IV HF, of whom 5426 had a history of previous HF hospitalization. Cox proportional hazards regression models were used to assess the association between time from previous HF hospitalization and randomization and the primary outcome of cardiovascular death or unplanned admission to hospital for the management of worsening HF during a median of 36.6 months. For patients with HF and reduced or preserved ejection fraction, rates of cardiovascular mortality and HF hospitalization were higher among patients with previous HF hospitalization than those without. The risk for mortality and hospitalization varied inversely with the time interval between hospitalization and randomization. Rates were higher for patients with HF and reduced ejection fraction within each category. Event rates for those with HF with preserved ejection fraction and a HF hospitalization in the 6 months before randomization were comparable with the rate in patients with HF and reduced ejection fraction with no previous HF hospitalization. CONCLUSIONS: Rates of cardiovascular death or HF hospitalization are greatest in those who have been previously hospitalized for HF. Independent of EF, rates of death and readmission decline as time from HF hospitalization to trial enrollment increased. Recent HF hospitalization identifies a high-risk population for future clinical trials in HF and reduced ejection fraction and HF with preserved ejection fraction. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00634400.
Authors: Daniel Levy; Satish Kenchaiah; Martin G Larson; Emelia J Benjamin; Michelle J Kupka; Kalon K L Ho; Joanne M Murabito; Ramachandran S Vasan Journal: N Engl J Med Date: 2002-10-31 Impact factor: 91.245
Authors: John S Gottdiener; Robyn L McClelland; Robert Marshall; Lynn Shemanski; Curt D Furberg; Dalane W Kitzman; Mary Cushman; Joseph Polak; Julius M Gardin; Bernard J Gersh; Gerard P Aurigemma; Teri A Manolio Journal: Ann Intern Med Date: 2002-10-15 Impact factor: 25.391
Authors: Jerry H Gurwitz; David J Magid; David H Smith; Robert J Goldberg; David D McManus; Larry A Allen; Jane S Saczynski; Micah L Thorp; Grace Hsu; Sue Hee Sung; Alan S Go Journal: Am J Med Date: 2013-03-14 Impact factor: 4.965
Authors: Jeptha P Curtis; Seth I Sokol; Yongfei Wang; Saif S Rathore; Dennis T Ko; Farid Jadbabaie; Edward L Portnay; Stephen J Marshalko; Martha J Radford; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Christopher B Granger; John J V McMurray; Salim Yusuf; Peter Held; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Marc A Pfeffer; Karl Swedberg Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Romano Endrighi; Andrew J Waters; Stephen S Gottlieb; Kristie M Harris; Andrew J Wawrzyniak; Nadine S Bekkouche; Yisheng Li; Willem J Kop; David S Krantz Journal: Heart Date: 2016-06-29 Impact factor: 5.994
Authors: Jacob P Kelly; Robert J Mentz; Alexandre Mebazaa; Adriaan A Voors; Javed Butler; Lothar Roessig; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor; Carolyn S P Lam Journal: J Am Coll Cardiol Date: 2015-04-28 Impact factor: 24.094
Authors: Marin Nishimura; Harpreet Bhatia; Janet Ma; Stephen D Dickson; Laith Alshawabkeh; Eric Adler; Alan Maisel; Michael H Criqui; Barry Greenberg; Isac C Thomas Journal: Am J Med Date: 2019-07-29 Impact factor: 4.965
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Cherinne Arundel; Phillip H Lam; Rahul Khosla; Marc R Blackman; Gregg C Fonarow; Charity Morgan; Qing Zeng; Ross D Fletcher; Javed Butler; Wen-Chih Wu; Prakash Deedwania; Thomas E Love; Michel White; Wilbert S Aronow; Stefan D Anker; Richard M Allman; Ali Ahmed Journal: Am J Med Date: 2016-07-09 Impact factor: 4.965
Authors: Yogesh N V Reddy; Masaru Obokata; Aaron D Jones; Gregory D Lewis; Sanjiv J Shah; Omar F Abouezzedine; Marat Fudim; Brooke Alhanti; Lynne W Stevenson; Margaret M Redfield; Barry A Borlaug Journal: J Card Fail Date: 2020-08-19 Impact factor: 5.712
Authors: Muthiah Vaduganathan; Brian L Claggett; Akshay S Desai; Stefan D Anker; Sergio V Perrone; Stefan Janssens; Davor Milicic; Juan L Arango; Milton Packer; Victor C Shi; Martin P Lefkowitz; John J V McMurray; Scott D Solomon Journal: J Am Coll Cardiol Date: 2019-11-11 Impact factor: 24.094
Authors: David D Berg; Eugene Braunwald; Adam D DeVore; Anuradha Lala; Sean P Pinney; Carol I Duffy; Yared Gurmu; Eric J Velazquez; David A Morrow Journal: JACC Heart Fail Date: 2020-08-12 Impact factor: 12.035